The genomics of heart failure: design and rationale of the HERMES consortium.
Lumbers RT., Shah S., Lin H., Czuba T., Henry A., Swerdlow DI., Mälarstig A., Andersson C., Verweij N., Holmes MV., Ärnlöv J., Svensson P., Hemingway H., Sallah N., Almgren P., Aragam KG., Asselin G., Backman JD., Biggs ML., Bloom HL., Boersma E., Brandimarto J., Brown MR., Brunner-La Rocca H-P., Carey DJ., Chaffin MD., Chasman DI., Chazara O., Chen X., Chen X., Chung JH., Chutkow W., Cleland JGF., Cook JP., de Denus S., Dehghan A., Delgado GE., Denaxas S., Doney AS., Dörr M., Dudley SC., Engström G., Esko T., Fatemifar G., Felix SB., Finan C., Ford I., Fougerousse F., Fouodjio R., Ghanbari M., Ghasemi S., Giedraitis V., Giulianini F., Gottdiener JS., Gross S., Guðbjartsson DF., Gui H., Gutmann R., Haggerty CM., van der Harst P., Hedman ÅK., Helgadottir A., Hillege H., Hyde CL., Jacob J., Jukema JW., Kamanu F., Kardys I., Kavousi M., Khaw K-T., Kleber ME., Køber L., Koekemoer A., Kraus B., Kuchenbaecker K., Langenberg C., Lind L., Lindgren CM., London B., Lotta LA., Lovering RC., Luan J., Magnusson P., Mahajan A., Mann D., Margulies KB., Marston NA., März W., McMurray JJV., Melander O., Melloni G., Mordi IR., Morley MP., Morris AD., Morris AP., Morrison AC., Nagle MW., Nelson CP., Newton-Cheh C., Niessner A., Niiranen T., Nowak C., O'Donoghue ML., Owens AT., Palmer CNA., Paré G., Perola M., Perreault L-PL., Portilla-Fernandez E., Psaty BM., Rice KM., Ridker PM., Romaine SPR., Roselli C., Rotter JI., Ruff CT., Sabatine MS., Salo P., Salomaa V., van Setten J., Shalaby AA., Smelser DT., Smith NL., Stefansson K., Stender S., Stott DJ., Sveinbjörnsson G., Tammesoo M-L., Tardif J-C., Taylor KD., Teder-Laving M., Teumer A., Thorgeirsson G., Thorsteinsdottir U., Torp-Pedersen C., Trompet S., Tuckwell D., Tyl B., Uitterlinden AG., Vaura F., Veluchamy A., Visscher PM., Völker U., Voors AA., Wang X., Wareham NJ., Weeke PE., Weiss R., White HD., Wiggins KL., Xing H., Yang J., Yang Y., Yerges-Armstrong LM., Yu B., Zannad F., Zhao F., Regeneron Genetics Center ., Wilk JB., Holm H., Sattar N., Lubitz SA., Lanfear DE., Shah S., Dunn ME., Wells QS., Asselbergs FW., Hingorani AD., Dubé M-P., Samani NJ., Lang CC., Cappola TP., Ellinor PT., Vasan RS., Smith JG.
AIMS: The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure. METHODS AND RESULTS: The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome-wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow-up following heart failure diagnosis ranged from 2 to 116 months. Forty-nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34-90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of ≥1.10 for common variants (allele frequency ≥ 0.05) and ≥1.20 for low-frequency variants (allele frequency 0.01-0.05) at P < 5 × 10-8 under an additive genetic model. CONCLUSIONS: HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction.